The strong safety and efficacy proof-of-concept data, combined with FDA alignment on a pivotal endpoint and a larger-than-expected addressable patient population, significantly de-risk the OPGx-BEST1 program. Traders should watch for Cohort 2 data in Q2 2027 and initiation of the pivotal trial later in 2027, which are the next major catalysts. The stock may re-rate on the reduced clinical and regulatory risk profile.
Price Chart
Executive Summary
Opus Genetics reported positive 3- and 6-month data from the low-dose Cohort 1 of its Phase 1/2 trial for OPGx-BEST1 in BEST1-related retinal diseases. All five participants showed functional improvement, 75% of evaluable participants met the FDA-aligned microperimetry endpoint, and the therapy was well-tolerated with no serious adverse events. The company also announced a successful FDA Type C meeting aligning on a potential pivotal endpoint, over-enrollment of Cohort 2, and a new epidemiology estimate of 23,600 symptomatic U.S. patients, de-risking the program and supporting a path to pivotal trials in 2027.
Key Facts
- All 5 participants in low-dose Cohort 1 showed clinically meaningful improvement in visual function (BCVA, LLVA, contrast sensitivity, or microperimetry).
- 75% (3/4) of evaluable participants met the FDA-aligned microperimetry endpoint of >3 dB improvement in >5 prespecified loci.
- No serious adverse events, dose-limiting toxicities, or intraocular inflammation were observed; all treatment-related AEs were mild/moderate.
- FDA aligned on a potential pivotal endpoint: 3 dB microperimetry improvement in 5 prespecified loci with a patient-reported outcome in a randomized controlled trial.
- Cohort 2 (higher dose, 4.5x10^9 vg/eye) was over-enrolled to 8 participants; dosing expected to complete Q4 2026 with topline 3-month data in Q2 2027.
- New epidemiology estimates 23,600 symptomatic BEST1 patients in the U.S. and ~45,400 globally, suggesting a larger addressable market than previously thought.
- Cash runway extends into 2029, funding five clinical programs through multiple inflection points.
Financial Impact
No financial figures reported in the filing. The company's cash runway is stated to extend into 2029, supporting five clinical programs.
Risk Factors
- Data are from a small, open-label Phase 1/2 cohort (n=5) and may not be predictive of results in larger, controlled trials.
- Cohort 2 and pivotal trial results are still pending; higher-dose safety and efficacy are unproven.
- The company is pre-revenue and will require additional capital before commercialization; cash runway into 2029 is an estimate.
- Competition from other gene therapy or treatment modalities for inherited retinal diseases could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035979 |
| Document: ef20081753_8k.htm | 0001140361-26-035979 |
| Document: ef20081753_ex99-1.htm | 0001140361-26-035979 |
| Document: 0001140361-26-035979-index-headers.html | 0001140361-26-035979 |
| Document: 0001140361-26-035979-index.html | 0001140361-26-035979 |
| Document: 0001140361-26-035979.txt | 0001140361-26-035979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers